Is there a rationale for bladder cancer screening?
Screening should decrease disease-related mortality by detecting cancer before symptoms prompt evaluation. Several characteristics of bladder cancer make screening an attractive option. Nevertheless, premature adoption of a screening program has considerable negative consequences. This article reviews the current literature regarding screening for bladder cancer and emphasizes the need for prospective, clinical trials before considering practice modification.
Svatek
Robert S
RS
Lotan
Yair
Y
D014408:Biomarkers, Tumor / Q000652:urine; D003362:Cost-Benefit Analysis; D003558:Cystoscopy / Q000592:standards; D042241:Early Diagnosis; D005189:False Positive Reactions; D017048:Health Care Costs; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods / Q000592:standards; D015995:Prevalence; D012680:Sensitivity and Specificity; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality
D014408:Biomarkers, Tumor